BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10408158)

  • 1. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
    Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
    Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
    Shimada M; Uchida H; Kasahara T; Fuji K; Ogawa Y; Yoshida H; Hamajima T; Matsuda N; Ikeuchi T; Kai Y; Hiramori M; Hoshino M; Inoue K; Higaki Y
    Hinyokika Kiyo; 1998 Jul; 44(7):525-32. PubMed ID: 9752613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol].
    Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Higashi Y; Negishi T
    Hinyokika Kiyo; 1995 Mar; 41(3):191-6. PubMed ID: 7741071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
    Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
    Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
    Akaza H; Usami M; Kotake T; Koiso K; Aso Y
    Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.
    Sekido N; Kawai K; Akaza H; Koiso K
    Jpn J Clin Oncol; 1995 Aug; 25(4):164-7. PubMed ID: 7545251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preventive effect of chlormadinone acetate on flare-up phenomenon in advanced prostate cancer administered with a luteinizing hormone-releasing hormone analogue].
    Sato N; Kotake T; Masai M; Sakai S; Ito H
    Hinyokika Kiyo; 2000 Jan; 46(1):1-7. PubMed ID: 10723656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
    Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies on changes in the ratio of free to total PSA after endocrine treatment of prostate carcinoma].
    Sumi S; Umeda H; Yano M; Koga F; Arai K; Imai T; Hosoya Y; Maeda S; Honda M; Suzuki T; Yoshida K
    Hinyokika Kiyo; 1996 Dec; 42(12):937-41. PubMed ID: 9013228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dynamic study of the hormonal levels and tumor markers after the first administration of long-acting LH-RH analogue in patients with prostate cancer].
    Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Uchijima Y; Saitoh H
    Hinyokika Kiyo; 1994 May; 40(5):393-400. PubMed ID: 7517620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment with chlormadinone acetate eliminates testosterone surge induced by a luteinizing-hormone-releasing hormone analogue and the risk of disease flare in patients with metastatic carcinoma of the prostate.
    Yoshida K; Takeuchi S
    Eur Urol; 1995; 27(3):187-91. PubMed ID: 7541358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of chlormadinone acetate-pellet implantation and orchidectomy on benign prostatic hypertrophy in the dog.
    Kawakami E; Tsutsui T; Shimizu M; Orima H; Fujita M; Ogasa A
    Int J Androl; 1995 Oct; 18(5):248-55. PubMed ID: 8567095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of luteinizing hormone-releasing hormone (LH-RH) analogue on the function of the isolated rabbit corpus cavernosum.
    Itoh Y; Ando M; Ohmura M; Kondo A; Miyake K; Saito M
    Hinyokika Kiyo; 1996 Mar; 42(3):215-20. PubMed ID: 8619392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.